Skip to main content

Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.

Publication ,  Journal Article
Englund, JA; Raskino, C; Vavro, C; Palumbo, P; Ross, LL; McKinney, R; Nikolic-Djokic, D; Colgrove, RC; Baker, CJ ...
Published in: Pediatr Infect Dis J
January 2004

BACKGROUND: Few data are available concerning the impact of antiretroviral resistance in response to antiviral therapy in children. We evaluated the development of antiretroviral genotypic resistance and clinical outcome in a subgroup of children involved in a prospective antiretroviral therapy trial (Pediatric AIDS Clinical Trials Group Protocol 152). DESIGN: We studied 26 matched case/control pairs. A case was defined as having clinical disease progression during the study period; controls did not have disease progression. Cases and controls were matched by age and CD4+ cell count at baseline. Matched pairs received treatment with zidovudine (9 pairs), didanosine (12 pairs) or combined therapy (5 pairs). Multiple codons of the reverse transcriptase coding region (41, 67, 70, 74, 151, 184, 210, 215 and 219) were analyzed. Patients were evaluated for CD4+ cell count, HIV-1 viral load and HIV-1 biologic phenotype at baseline and clinical endpoint. RESULTS: The presence of mutations associated with resistance after nucleoside antiretroviral therapy (P = 0.039) and syncytium-inducing phenotype (P = 0.031), were significantly associated with increased risk of clinical disease progression. The mean difference in HIV-1 RNA levels between cases and their matched controls after nucleoside antiretroviral therapy was 0.77 log10 copies/ml higher for cases (P = 0.003). The median difference between cases and controls for CD4+ cell count after nucleoside antiretroviral therapy was 349 cells/mm3 lower for cases (P < 0.001). CONCLUSIONS: In this small prospective study of HIV-infected children, mutations in the reverse transcriptase coding region, syncytium-inducing viral phenotype, higher HIV-1 RNA load and lower CD4+ cell count were significantly correlated with increased risk of HIV clinical disease progression.

Duke Scholars

Published In

Pediatr Infect Dis J

DOI

ISSN

0891-3668

Publication Date

January 2004

Volume

23

Issue

1

Start / End Page

15 / 22

Location

United States

Related Subject Headings

  • Zidovudine
  • Viral Load
  • Statistics, Nonparametric
  • Reverse Transcriptase Inhibitors
  • Reference Values
  • RNA, Viral
  • Prospective Studies
  • Probability
  • Polymerase Chain Reaction
  • Phenotype
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Englund, J. A., Raskino, C., Vavro, C., Palumbo, P., Ross, L. L., McKinney, R., … Pediatric AIDS Clinical Trials Group Protocol 152 Team, . (2004). Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J, 23(1), 15–22. https://doi.org/10.1097/01.inf.0000105105.80229.ba
Englund, Janet A., Claire Raskino, Cindy Vavro, Paul Palumbo, Lisa L. Ross, Ross McKinney, Divna Nikolic-Djokic, Robert C. Colgrove, Carol J. Baker, and Carol J. Pediatric AIDS Clinical Trials Group Protocol 152 Team. “Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.Pediatr Infect Dis J 23, no. 1 (January 2004): 15–22. https://doi.org/10.1097/01.inf.0000105105.80229.ba.
Englund, Janet A., et al. “Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.Pediatr Infect Dis J, vol. 23, no. 1, Jan. 2004, pp. 15–22. Pubmed, doi:10.1097/01.inf.0000105105.80229.ba.
Englund JA, Raskino C, Vavro C, Palumbo P, Ross LL, McKinney R, Nikolic-Djokic D, Colgrove RC, Baker CJ, Pediatric AIDS Clinical Trials Group Protocol 152 Team. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J. 2004 Jan;23(1):15–22.

Published In

Pediatr Infect Dis J

DOI

ISSN

0891-3668

Publication Date

January 2004

Volume

23

Issue

1

Start / End Page

15 / 22

Location

United States

Related Subject Headings

  • Zidovudine
  • Viral Load
  • Statistics, Nonparametric
  • Reverse Transcriptase Inhibitors
  • Reference Values
  • RNA, Viral
  • Prospective Studies
  • Probability
  • Polymerase Chain Reaction
  • Phenotype